Literature DB >> 21550804

Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations.

Mariana Ferreira1, Teresinha Evangelista, Lígia S Almeida, João Martins, Maria Carmo Macario, Esmeralda Martins, Ana Moleirinho, Luísa Azevedo, Laura Vilarinho, Filippo M Santorelli.   

Abstract

Diseases affecting mtDNA stability, termed nuclear-mitochondrial intergenomic communication disorders, are caused by a primary nuclear gene defect resulting in multiple mtDNA deletions. The aim of this study was to estimate the frequency of known etiologies and the spectrum of mutations in a cohort of 21 patients harboring multiple mtDNA deletions in skeletal muscle. We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln). The novel mutations affect evolutionary conserved residues and were absent in a large set of control chromosomes. These findings expand the array of mutations associated with multiple rearranged mtDNA attributed to mutations in POLG. The relatively high diagnostic yield (about one in two cases) supports the notion that it is recommended to test POLG routinely in diagnostic laboratories whenever multiple mtDNA deletions are present, regardless of the age of onset of patients and their clinical phenotype.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550804     DOI: 10.1016/j.nmd.2011.03.011

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Novel POLG mutations and variable clinical phenotypes in 13 Italian patients.

Authors:  Paola Da Pozzo; Elena Cardaioli; Anna Rubegni; Gian Nicola Gallus; Alessandro Malandrini; Alessandra Rufa; Carla Battisti; Maria Alessandra Carluccio; Raffaele Rocchi; Fabio Giannini; Amedeo Bianchi; Michelangelo Mancuso; Gabriele Siciliano; Maria Teresa Dotti; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01-27       Impact factor: 3.307

2.  Mapping 136 pathogenic mutations into functional modules in human DNA polymerase γ establishes predictive genotype-phenotype correlations for the complete spectrum of POLG syndromes.

Authors:  Gregory A Farnum; Anssi Nurminen; Laurie S Kaguni
Journal:  Biochim Biophys Acta       Date:  2014-02-07

3.  Neuromyopathy with congenital cataracts and glaucoma: a distinct syndrome caused by POLG variants.

Authors:  Claudia Castiglioni; Fabiana Fattori; Bjarne Udd; Maria de Los Angeles Avaria; Bernardita Suarez; Adele D'Amico; Alessandro Malandrini; Rosalba Carrozzo; Daniela Verrigni; Enrico Bertini; Giorgio Tasca
Journal:  Eur J Hum Genet       Date:  2018-01-22       Impact factor: 4.246

4.  A non-radioactive DNA synthesis assay demonstrates that elements of the Sigma 1278b Mip1 mitochondrial DNA polymerase domain and C-terminal extension facilitate robust enzyme activity.

Authors:  Matthew J Young; Robin J Imperial; Suman Lakhi; Deborah A Court
Journal:  Yeast       Date:  2021-01-26       Impact factor: 3.239

5.  Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation.

Authors:  Monica Bandettini di Poggio; Claudia Nesti; Claudio Bruno; Maria Chiara Meschini; Angelo Schenone; Filippo M Santorelli
Journal:  BMC Med Genet       Date:  2013-10-07       Impact factor: 2.103

6.  A novel MTTT mutation m.15933G > A revealed in analysis of mitochondrial DNA in patients with suspected mitochondrial disease.

Authors:  Heidi K Soini; Antti Väisänen; Mikko Kärppä; Reetta Hinttala; Laura Kytövuori; Jukka S Moilanen; Johanna Uusimaa; Kari Majamaa
Journal:  BMC Med Genet       Date:  2017-02-10       Impact factor: 2.103

7.  De Novo Development of mtDNA Deletion Due to Decreased POLG and SSBP1 Expression in Humans.

Authors:  Yeonmi Lee; Taeho Kim; Miju Lee; Seongjun So; Mustafa Zafer Karagozlu; Go Hun Seo; In Hee Choi; Peter C W Lee; Chong-Jai Kim; Eunju Kang; Beom Hee Lee
Journal:  Genes (Basel)       Date:  2021-02-17       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.